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Introduction: During aging, advanced glycation end products (AGEs) accumulate in articular cartilage. In this study
we determined whether AGEs induce endoplasmic reticulum (ER) stress and studied the ER stress-activated path-
ways that stimulate cyclooxygenase-2 (COX-2) expression in human chondrocytes.
Methods: Chondrocytes were stimulated with AGE-BSA. Gene expression was determined by quantitative PCR and
protein expression was studied by immunoblotting. Studies to elucidate involved pathways were executed using
siRNAs and speciﬁc inhibitors of eukaryotic initiation factor-2α (eIF2α), MAPKs and NF-κB.
Results: AGE-BSA induced expression of GRP78 with concomitant increase in COX-2 expression was observed in
human chondrocytes. In addition, expression of Bag-1, an ER stress marker was also increased by AGE-BSA.
RAGE knockdown inhibited AGE-BSA-induced expression of GRP78 and COX-2. Treatment with eIF2α inhibitor
or eIF2α knockdown inhibited AGE-BSA-induced expression of GRP78 and COX-2 with decreased PGE2 produc-
tion. Treatment with SB202190 inhibited AGE-BSA-induced expression of GRP78 and COX-2, while treatment
with PD98051 inhibited AGE-BSA-induced GRP78 protein expression but had no effect on COX-2 protein expres-
sion. SP600125 had no effect on either GRP78 or COX-2 protein expression. Bay 11-7082 suppressed
AGE-BSA-induced GRP78 and COX-2 expression. AGE-BSA-induced activation of NF-κB was inhibited by treat-
ment with SB202190 and by eIF2α knockdown, but was not inhibited when chondrocytes were treated with
SP600125 or PD98059.
Conclusion: This study demonstrates that AGEs induce ER stress and stimulate the expression of COX-2 through
eIF2α, p38-MAPK and NF-κB pathways in human chondrocytes. Our results provide important insights into car-
tilage degradation in osteoarthritis associated with latent ER stress.© 2012 Elsevier B.V. All rights reserved.1. Introduction
In the endoplasmic reticulum (ER), secretory and transmembrane
proteins fold into their native conformation andundergo posttranslation-
al modiﬁcations important for their activity and structure [1]. Interfer-
ence with proper protein folding activity results in the accumulation of
misfolded proteins in ER, a phenomenon commonly referred to as ER
stress [1,2]. To help proteins fold properly, ER contains a master molecu-
lar chaperone GRP78 (BiP). When protein folding is disturbed, GRP78
synthesis is increased and GRP78 subsequently binds to misfolded pro-
teins to prevent them from forming aggregates and assists them to refold
properly [3]. Bag-1 has recently been shown to be a downstreamress; OA, osteoarthritis; AGEs,
GEs; GRP78, glucose regulated
1;eIF2‐α, eukaryotic initiation
in E2; p38‐MAPK, p38‐mitogen
edicine, Qassim University,
sheed).
rights reserved.regulator of ER stress in chondrocytes [4]. It is now well established
that overexpression of Bag-1 protects chondrocytes from ER stress [4,5].
Therefore elevated expressions of GRP78 and Bag-1 are considered to
be reliable markers of ER stress [3,4]. The ER stress response is suggested
to contribute in several human diseases, including osteoarthritis (OA)
and rheumatoid arthritis (RA) [2].
OA, the most common forms of arthritis, is a progressive degener-
ative joint disease that has a major impact on joint function and the
patient's quality of life [6]. The most important risk factor for OA be-
sides female sex, obesity, and joint trauma is aging [6,7]. However,
it is relatively unknown how aging contributes to the onset and pro-
gression of OA. Advanced glycation end products (AGEs) are pro-
duced by the non-enzymatic glycation of macromolecules and
accumulate in a number of different tissues [8]. In articular cartilage,
accumulation of AGEs makes the collagen network brittle thus in-
creasing the risk for the development of OA [8,9]. The biological activ-
ities of AGEs are thought to be mediated by speciﬁc receptors for AGE
(RAGE) and activation of RAGE engages critical signaling pathways
linked to pro-inﬂammatory responses and activation of various in-
ﬂammatory genes [10]. Chondrocytes are secretory cells and are the
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synthesis and turnover of extracellular matrix (ECM) [11]. In OA, ac-
tivation of RAGE has been shown to stimulate chondrocytes, resulting
in increased production of cartilage degrading enzymes through the
activation of intracellular signaling pathways comprising of MAPKS,
and NF-κB [12,13]. Despite studies on AGEs induced cartilage destruc-
tion in OA, ER stress related cartilage degradation remains nebulous.
Signal transduction from theER to the cell nucleus could bemediated
by a signaling cascade similar to theplasmamembrane-initiated cell sig-
naling. ER stress, for example, is coupled to the activation of stress-
activated protein kinases such as MAP kinases [15,16]. Members of the
MAPK family phosphorylate a number of transcription factors including
NF-κB, with subsequent induction of inﬂammatory genes expres-
sion [14]. p38-MAPK, in particular, is activated by a diverse array of ER
stress inducing agents such as tunicamycin [15] and its activation is as-
sociatedwith inﬂammation and cartilage and bone destruction [17] as it
regulates cytokine production through a variety of transcriptional and
translational mechanisms [18]. In a rodent model of inﬂammatory ar-
thritis, p38-MAPK inhibition suppressed the inﬂammation and bone de-
struction [19]. Phosphorylation of the subunit of eukaryotic initiation
factor-2 (eIF2) is another important mechanism involved in the regula-
tion of protein synthesis during ER stress [extensively reviewed in [20]
and is required for the activation of NF-κB [21]. Activation of NF-κB by
ER stress leads to induction of many cellular genes that are largely
anti-apoptotic in function [22]. Now, it is well established that under
the inﬂuence of inﬂammation, COX-2 is upregulated, which results in a
disturbed cartilage matrix turnover [23–25]. It is also reported that se-
lective COX-2 inhibition prevents proinﬂammatory cytokine-induced
cartilage damage [23,24]. Furthermore, over expression of COX-2 me-
diated PGE2 production has been found in OA and was linked to OA
progression and drug resistance [25,26]. Chondrocytes are thought
to be the major source of PGE2 production in OA joints and suppres-
sion of COX-2 expression and PGE2 production was found to be
chondroprotective [25].
Although AGEs have been shown to induce the inﬂammatory re-
sponse via activation of NF-κB andMAPKs in various cell types including
chondrocytes, but whether they induce the ER stress in chondrocytes
has not yet been reported. In this report, we demonstrate that AGEs in-
duce ER stress which leads to increased expression of COX-2 in human
chondrocytes. Our results also showed that in human chondrocytes
with ER stress induction of COX-2 was mediated through eIF2α,
p38-MAPK and NF-κB pathways.
2. Patients, materials and methods
2.1. Cartilage selection and chondrocytes preparation
With Institutional Review Board (IRB) approval, discarded cartilage
samples were obtained from the knee or hip joints of 44 OA patients
aged 38–69 years (32 female and 12 male Caucasian; mean age, 48±
26 years) who underwent joint replacement surgery at Metrohealth
Medical Center, Cleveland, OH. The macroscopic cartilage degeneration
was determined by staining of femoral head samples with India ink
[27], and the cartilage with smooth articular surface (unaffected carti-
lage)was resected andused to prepare chondrocytes by enzymatic diges-
tion as previously described [14,28,29]. Histological analysis of the
unaffected cartilage samples was performed on 5-μm-thick sections
stained with H & E and Safranin O and graded using the Mankin score
[30]. Grading of the histology slides revealed that all of the cartilage
pieces taken from the unaffected area had a Mankin score b2 for struc-
ture and a Mankin score of 1 for cellularity. Normal cartilage samples
were obtained from trauma patients (n=2) with no known history of
OA or RA. Isolated chondrocytes were plated at a density of 1.2×106/ml
in 35-mm tissue culture dishes (0.125×106 cells/cm2) in complete
DMEM/Ham's F-12medium as previously described [14,28]. Only prima-
ry human OA chondrocytes were used in studies described here.2.2. AGE-BSA preparation
AGE-BSA was prepared by reacting BSA (Sigma Chemical Co., St
Louis, MO, USA) with glycoaldehyde (Sigma), according to the meth-
od described by Valencia and colleagues [31] with slight modiﬁca-
tions. Brieﬂy, endotoxin-free BSA (2 mg/ml) was incubated under
nonreducing conditions with 70 mM fresh glycoaldehyde in PBS
(pH 7.4) without calcium chloride and magnesium chloride for
3 days at 37 °C. The reaction was terminated by removing nonreacted
glycoaldehyde by dialyzing extensively against PBS.
Endotoxicity of glycoaldehyde was also tested on chondrocytes by
incubating with freshly prepared glycoaldehyde (1–50 μM) and was
found to be non-toxic for tested chondrocytes.
2.3. Treatment of chondrocytes with AGE-BSA and inhibitors for MAPKs,
eIF2α and NF-κB
Human OA chondrocytes (1.2×106/ml) were plated in 35 mm cul-
ture dishes (0.125×106 cells/cm2) in complete DMEM/Hams-F12medi-
um and serum-starved for 12 h/overnight and then treated with
5–100 μg/ml of AGE-BSA for 0–24 h. Primary chondrocyteswere treated
with MAPKs, eIF2α or NF-κB inhibitors for 1 h prior to stimulation with
AGE-BSA. Chondrocytes cultured without AGE-BSA or cultured with na-
tive BSA served as controls. Inhibitors used were SB202190 (catalog
#1264, R&D Systems Inc., MN), SP600125 (catalog #40119, Calbiochem,
MA); PD98059 (catalog #513000, Calbiochem); 2 Aminopurine (catalog
#A3509, Sigma, St. Louis, MO), Bay 11–7082 (catalog #B5556, Sigma).
The concentration of SB202190, SP600125, PD98059, 2 Aminopurine
(2AP), Bay 11–7082 used in the study was 100 μM, 10 μM, 50 μM,
10 μM, 10 μM, respectively.
2.4. Knockdown of RAGE and eIF2α by transfection with small interfering
RNA (siRNA)
Human OA chondrocytes were transfected with human RAGE-
speciﬁc siRNA (On-Target SMARTPool, catalog#L00362500, Dharmacon
RNA Technologies, Lafayette, CO), eIF2α-speciﬁc siRNA (catalog #sc-
35272, Santa Cruz Biotechnology, CA) or with a negative human
GAPDH control siRNA (catalog #D-0018301020, Dharmacon) using
Amaxa Human Chondrocytes Nucleofector Kit (catalogue #VPF-
1001, Lonza, Walkersville, MD). Transfection efﬁciency was monitored
with red ﬂuorescent siRNA oligonucleotides (siGLO red indicator,
catalogue #D0016300220, Dharmacon). Approximately 70–80% of the
chondrocytes emitted red ﬂuorescence signal when transfected with
siGLO.
2.5. Cell viability assays
Human OA chondrocytes viability after nucleofection was exam-
ined using the CytoTox-Glo™ Luminescent Cell Viability Assay Kit
(Promega, Madison, WI). The viability of the transfected cell was
70% in comparison to non-transfected cells. Whereas AGE-BSA or in-
hibitors used in the study have no cytotoxic effect on human OA
chondrocytes.
2.6. Real time-PCR
Real time quantitative polymerase chain reaction (qRT-PCR) was
used to quantify the expression of mRNAs for GRP78 and COX-2
with expression of GAPDH as endogenous control. Primers used for
PCR assisted ampliﬁcation were listed in Table 1. PCR ampliﬁcation
was carried out using the core kit for SYBR Green or Taqman (Applied
Biosystem, Foster City, CA) and the Step One Real Time PCR System
(Applied Biosystems). Typical proﬁle times used were initial step,
95 °C for 10 minutes, followed by a second step at 95 °C for 15 sec
and 60 °C for 60 sec for 40 cycles with melting curve analysis. The
2181Z. Rasheed, T.M. Haqqi / Biochimica et Biophysica Acta 1823 (2012) 2179–2189level of target mRNA was normalized to the level of GAPDH and com-
pared to control (untreated sample). Data was analyzed using com-
parative ΔΔCT method [32].
2.7. Western immunoblotting
Stimulated and control human OA chondrocytes were washed
with cold PBS and lysed using the cell lysis RIPA buffer (50 mM
Tris:HCl, pH 7.5; 150 mM NaCl; 1% IGEPAL, 4 mM EDTA, 0.1% sodium
deoxycholate; 10 mM Na4P2O7, 10 mM NaF, 2 mM Na3VO4, 1 mM
PMSF, 1 μg/ml leupeptin, 1 μg/ml aprotinin). Cytoplasmic and nuclear
fractions were prepared as previously described [33]. Blots were ana-
lyzed as described previously [33,34] and images were captured using
AFP-Imaging System (Minimedical Series, Elms Ford, NY).
2.8. Enzyme-linked immunosorbent assay (ELISA)
Human OA chondrocytes were stimulated with or without
AGE-BSA (100 μg/ml) for 0–24 h. PGE2 produced in the culture medi-
um was quantiﬁed using commercially available ELISA kit (Cayman
Chemical Company, Ann Arbor, MI). Plates were read using Synergy
HT microplate reader (Biotek Instrument, Winooski, VT).
2.9. NF-κB activity assays
Activation of NF-κBp65 in AGE-BSA stimulated human OA
chondrocyteswas determined using a highly sensitive Transcription Fac-
tor ELISAKit (AssayDesigns, AnnArbor,MI). Activation of NF-κBp50 and
Rel B in AGE-BSA stimulated chondrocytes was determined by Western
immunoblotting using speciﬁc antibodies against NF-κBp50 and Rel B
(Cell signaling technology, Beverly, MA). Upregulation of NF-κBp50 by
AGE-BSA was further veriﬁed by Sandwich ELISA established in our lab-
oratory. Brieﬂy, ﬂat bottomed 96-well microtiter plates (polystryrene
polysorp immunoplates, Nunc-Immuno™ MicroWell, Sigma) were
coated with anti-NF-κBp50 (N-19) polyclonal antibodies (catalog
#sc-1191, Santa Cruz Biotechnology, CA; diluted 1:100 in coating buffer)
overnight at 4 °C. The plates were washed with TBS-Tween 20 and the
non-speciﬁc binding sites were blocked with TBS containing 1% BSA
(Sigma) at room temperature for 1 h. After washing extensively with
TBS-Tween 20, 100 μl of nuclear cell extracts (10 μg/ml) were added to
duplicate wells of the coated plate and incubated at room temperature
for 2 h and overnight at 4 °C. The plates were washed ﬁve times with
TBS-Tween 20 and 100 μl of anti-NF-κBp50 (D-6)monoclonal IgG (cata-
log #sc-166588, Santa Cruz Biotechnology; diluted 1:100)was incubated
at room temperature for 2 h. The plates were washed extensively and
100 μl of anti-human IgG-horseradish peroxidase (catalog #sc2769,
Santa Cruz Biotechnology)was added and incubated for 2 h. Afterwash-
ing, 100 μl of 3,3′,5,5′-Tetramethylbenzidine peroxidase substrate (TMB,Table 1
Sequences of primers used in gene expression studies.
Gene Accession
number
Forward primer Backward primer
GRP78 NM_005347 5′-TCC TGC GTC GGC GTG
T-3′
5′-GTT GCC CTG ATC GTT
GGC-3′
COX-2 NM_000963 5′-CAA ATC CTT GCT GTT
CCC ACC CAT-3′
5′-GTG CAC TGT GTT TGG
AGT GGG TTT-3′
GAPDH NM_002046 5′-TCG ACA GTC AGC CGC
ATC TTC TTT-3′
5′-ACC AAA TCC GTT GAC
TCC GAC CTT-3′
COL2A1 NM_001844 5′-ACG TGA AAG ACT GCC
TCA GC-3′
5′-TTT CAT CAA ATC CTC
CAG CC-3′
COL10A1 NM_000493 5′-TGA TCC TGG AGT TGG
AGG AC-3′
5′-GAG ATC GAT GAT GGC
ACT CC-3′
ACAN NM_013227 5′-GAC CTG CAA GGA GAC
AGA GG-3′
5′-CCA CTG GTA GTC CTT
GGG CAT-3′
SOX-9 NM_011448 5′-GAT TTT TCA CGC AGC
CCT AA-3′
5′-ATA CAG TCC AGG CAG
ACC CA-3′catalog #206697A, Santa Cruz Biotechnology) was added to each well.
The reactionwas stopped after 10 minutes by adding 100 μl of stop solu-
tion (2 M H2SO4) and OD was read at 450 nm on an automatic
microplate reader (Anthos Zenyth 3100 Multimode Detectors, Salzburg,
Austria).
2.10. Statistical analysis
All measurements were performed in triplicates and repeated at
least three times using chondrocytes prepared from different OA pa-
tients. Data sets were analyzed by analysis of variance followed by
Tukey's post hoc multiple comparison tests using Graph Pad Prism
version 5.0 (Graph Pad Software Inc., San Diego, CA) or Origin soft-
ware package version 5.0 (Origin Lab Corporation, Northampton,
MA). A p value of b0.05 was considered statistically signiﬁcant. Values
shown are mean with 95% CI unless stated otherwise.
3. Results
3.1. Human chondrocytes in monolayers maintain their chondrogenic
phenotype
We determined whether primary human chondrocytes used in
these studiesmaintained their phenotype - by analyzing the expression
of COL2A1, ACAN, and SOX-9 mRNA, which are considered to be signa-
tures of the chondrogenic phenotype [35]. PCR primers are listed in
Table 1. Our results show that primary human chondrocytes in mono-
layer culture maintained their phenotype, when they were plated
(1.2×106/ml) in 35-mm culture dishes (0.125×106 cells/cm2) in com-
plete DMEM with 10% FBS and were allowed to grow at 37 °C and 5%
CO2 in a tissue culture incubator, as judged by the continued expres-
sion of COL2A1, ACAN, and SOX-9 mRNAs, whereas COL10A1 mRNA
was not expressed (data not given). Based on these data, human
chondrocytes were used within 72 h after plating to avoid possible
dedifferentiation.
3.2. AGE-BSA induce ER stress and the expression of COX-2 in human
chondrocytes
This study comprised of 44 OA patients, out of which 24 OA pa-
tients primary chondrocytes showed up-regulation of mRNA and pro-
tein expression of ER stress marker GRP78, and COX-2 upon AGE-BSA
stimulation (pb0.05, Fig. 1A). Treatment of OA chondrocytes with a
well known ER stress inducer drug tunicamycin (TM), used as a pos-
itive control for ER stress, also increased the gene/protein expression
of GRP78 and COX-2 (Fig. 1B). Similarly, enhanced mRNA and protein
expression of COX-2 by AGE-BSA or by TM, subsequently increased
the production of PGE2 in the culture medium (Fig. 1A, B). To further
strengthen that AGE-BSA induced ER stress, we estimated the protein
expression of another ER stress marker protein Bag-1 [4,5] in
AGE-BSA stimulated human OA chondrocytes. Our results showed
that AGE-BSA time dependently induced the protein expression of
Bag-1 (p50/p36) in human OA chondrocytes (Fig. 1C). These ﬁnding
were further re-conﬁrmed by well known ER stress inducer
tunicamycin. Tunicamycin treated human OA chondrocytes also in-
creased the protein expression of Bag-1 (Fig. 1C). Similarly, human
OA chondrocytes were treated with native BSA (nBSA) and expres-
sion of GRP78, Bag1, COX-2 was determined. Our data showed that
nBSA was not involved in up-regulation of GRP78, Bag1, COX-2 or
PGE2 production in human OA chondrocytes (Fig. 1D). We have also
tested the role of AGE-BSA or nBSA on chondrocytes obtained from
normal cartilage. Normal human chondrocytes were stimulated
with either AGE-BSA or nBSA (100 μg/ml) for 0–24 h and levels of
GRP78, Bag1 and COX-2 was quantiﬁed by immunoblotting and com-
pared with the levels in untreated normal chondrocytes. Our results
showed that AGE-BSA increased the protein expression of GRP78,
Fig. 1. Elevated expression of GRP-78, Bag-1 and COX-2 in AGE-BSA stimulated human chondrocytes. (A) Human OA chondrocytes (70–80% conﬂuent) were treated with AGE-BSA
(100 μg/ml) for 0, 1, 6, 12 and 24 h. Gene expression of GRP78 and COX-2 was determined by real time quantitative PCR and normalized to GAPDH and compared to the levels
present in untreated OA chondrocytes using comparative ΔΔCT method. Cell lyastes were analyzed by immunoblotting with antibodies speciﬁc for GRP78 (cat. #3183, Cell Signaling
Tech), COX-2 (cat. #4842, Cell Signaling Tech) and β-actin (cat. #sc-47778, Santa Cruz Biotech). β-actin was used as a loading control. Production of PGE2 in the culture medium
was quantiﬁed by ELISA. (B) Human OA chondrocytes were treated with tunicamycin, TM (2.5 μM) for 0, 1, 6, 12 and 24 h. Gene or protein expressions were determined as
described in section A. (C) Bag-1 expression in human OA chondrocytes stimulated by AGE-BSA or TM. Cell lyastes were analyzed by immunoblotting with antibodies speciﬁc
for Bag-1 (cat. #sc-135844, Santa Cruz Biotech). (D) Human OA chondrocytes were treated with native (n)BSA (100 μg/ml) for 0, 1, 6, 12 and 24 h. Gene or protein expressions
were determined as described in section A. Western blots are from single chondrocytes sample, but are representative of three chondrocytes samples. Bars show the mean with
95% conﬁdence interval (CI) results of three independent assays, each of which run in triplicate experiments. *pb0.05 versus control; #pb0.0001 versus control.
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(Fig. 2A). Treatment of normal human chondrocytes with nBSA for
the same time points showed no increase in GRP78, Bag1 and
COX-2 expressions or PGE2 production (Fig. 2B).3.3. Necessity of RAGE for AGE-BSA stimulation of COX-2 during ER stress
in human chondrocytes
To determine whether AGE-BSA-induced expression of GRP78 and
COX-2 in primary human OA chondrocytes was mediated via binding
to RAGE, we used siRNA-mediated knockdown of RAGE expression in
OA chondrocytes. Transfection of human OA chondrocytes with
RAGE-speciﬁc siRNAs signiﬁcantly knocked down the expression of
RAGE and inhibited the AGE-BSA-induced GRP78 and COX-2 expres-
sion and PGE2 production (Fig. 3A and B). Taken together theseﬁndings provide strong evidence of the involvement of RAGE in
AGE-BSA-mediated induction of ER stress and the expression of
COX-2 in human OA chondrocytes.3.4. Activation of eIF2α is required for ER stress stimulated expression of
COX-2 in human OA chondrocytes
Treatment of primary human OA chondrocytes with AGE-BSA, in-
duced eIF2α phosphorylation in a time-dependent manner, and the
maximum increase over the basal levels was observed 24 h after the
treatment (Fig. 4A). To determine whether AGE-BSA-induced phos-
phorylation of eIF2α is required for the elevated expression of
COX-2, human chondrocytes were transfected with eIF2α-speciﬁc
siRNAs and then stimulated with AGE-BSA for 24 h. Total RNA was
isolated and then subjected to real time PCR. Our results showed
Fig. 2. Elevated expression of GRP78, Bag1 and COX-2 in AGE-BSA stimulated normal human chondrocytes. Normal human chondrocytes (70–80% conﬂuent) were treated with AGE-BSA
(100 μg/ml) (A) orwith nBSA (100 μg/ml) (B) for 0, 1, 6, 12 and24 h. Cell lyasteswere analyzed by immunoblottingwith antibodies speciﬁc for GRP78, COX-2.β-actinwas usedas a loading
control. Production of PGE2 in the culturemediumwas quantiﬁed by ELISA. Normal chondrocytes were obtained from trauma patients. Immunoblots are from single chondrocytes sample,
but are representative of two chondrocytes samples. Bars show themeanwith 95% CI results of two independent assays, eachofwhich run in triplicate experiments. *pb0.05 versus control;
#pb0.0001 versus control.
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mRNA expression of GRP78 and COX-2 (pb0.05; Fig. 4B). To deter-
mine whether mRNA inhibition of GRP78 and COX-2 by eIF2α knock-
down also affects the protein levels and the production of PGE2,Fig. 3. AGE-BSA induced ER stress is mediated through RAGE in human chondrocytes. (A) RA
OA chondrocytes. OA chondrocytes were transfected with RAGE-siRNA or control siRNA and
determined as described under Fig. 1. (B) Protein expression of RAGE, GRP78 and COX-2 was
of PGE2 was quantiﬁed by ELISA. Immunoblots are from single chondrocytes sample, but are
ﬁve independent assays, each of which run in triplicate experiments. #pb0.05 versus c
transfected with control siRNA alone.chondrocyte lysates were analyzed by Western immunoblotting for
GRP78 and COX-2 proteins and cell culture supernatants were
assayed for PGE2 production using ELISA. As shown in Fig. 4C, knock-
down of eIF2α signiﬁcantly inhibited the AGE-BSA-induced proteinGE-speciﬁc siRNA transfection on AGE-BSA-induced expression of GRP78 and COX-2 in
then stimulated with AGE-BSA for 24 h. (A) Expression of GRP78 and COX-2 mRNA was
determined by Immunoblot analysis. β-actin was used as a loading control. Production
representative of ﬁve chondrocytes samples. Bars show the mean with 95% CI results of
hondrocytes treated with AGE-BSA+control siRNA; *pb0.001 versus chondrocytes
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chondrocytes. Furthermore, treatment of human OA chondrocytes
with 2-aminopurine (2-AP), an inhibitor of eIF2α phosphorylation at-
tenuated the AGE-BSA-induced mRNA and protein expression of
GRP78, COX-2 and PGE2 production (Fig. 4D and E). Taken together,
these results clearly indicate that activating eIF2α is essential for
the AGE-BSA-induced ER stress and expression of COX-2 in human
OA chondrocytes.
3.5. MAPKs activation in human OA chondrocytes is required for the AGE-
BSA-induced COX-2 expression during ER stress
As the expression of COX-2 is regulated through the MAPKs path-
ways [15], we investigated whether these pathways played a role in
the induction of COX-2 during ER stress in AGEs stimulated OA
chondrocytes. Primary human OA chondrocytes were treated with
AGE-BSA for 0–24 h and the phosphorylation of p38-MAPK, JNK and
ERK was examined by Western immunoblotting. All three MAPKs
were phosphorylated in AGE-BSA-stimulated OA chondrocytes but
the duration of phosphorylation was different with phosphorylated
JNK being detectable for 1 h, p38-MAPK for 15 minutes while ERK
was found to be phosphorylated at all the time points analyzed
(Fig. 5A). To determine the relation of MAPKs p38, JNK, ERK activation
and GRP78 or COX-2 expressions in AGE-BSA-stimulated human OA
chondrocytes, we used pharmacological agents that inhibit activation
of p38-MAPK (SB202190), JNK (SP600125) and ERK (PD89059). OurFig. 4. AGE-BSA-induced stimulation of GRP78 and COX-2 ismediated throughα subunit of eIF
indicated times, the phosphorylation of eIF2αwas determined by immunobloting. (B) eIF2α-sp
OA chondrocytes. (C) eIF2α-speciﬁc siRNA transfection andprotein expression ofGRP78 and CO
gene expression of GRP78 and COX-2. OA chondrocytes were pretreated with 2AP (10 μM) for 2
and COX-2 or PGE2 production. OA chondrocytes were pretreated with 2AP for 2 h and stimu
chondrocytes sample, but are representative of three chondrocytes samples. Bars show themea
periments. *pb0.001 versus chondrocytes treatedwith AGE-BSA+control siRNA; #pb0.05 versu
AGE-BSA alone; $pb0.0001 versus untreated chondrocytes.results showed that pretreatment with SB202190 caused signiﬁcant
decrease in mRNA and protein expression of GRP78 (pb0.05) but in
contrast, treatment with the PD98059 and SP600125 had no signiﬁ-
cant effect on AGE-BSA induced GRP78 mRNA or protein expressions
compared to controls (Fig. 5A and B). Expression of COX-2 mRNA or
protein and PGE2 production in the culture medium was signiﬁcantly
inhibited with SB202190 treatment (pb0.05), whereas treatment
with SP600125 and PD98059 had no effect on AGE-BSA-induced
COX-2 expression and PGE2 production in AGE-BSA-stimulated OA
chondrocytes (pb0.05; Fig. 5 B&C). Taken together, our results dem-
onstrated that p38-MAPK is the only MAPK involved in AGE-BSA-
induced induction of ER stress characterized by the expression of
GRP78 and COX-2 in OA chondrocytes (Fig. 5B and C).
3.6. Induction of NF-κB is dependent on the activation of p38-MAPK and
eIF2α in AGE-BSA-stimulated human OA chondrocytes
To evaluate the mechanism of AGE-BSA induced expression of
COX-2 in OA chondrocytes with ER stress, NF-κB activation was stud-
ied in detailed. Stimulation of OA chondrocytes with AGE-BSA in-
duced the degradation of cytoplasmic IκBα and increased the
nuclear level of NF-κB subunits p65 and Rel-B (Fig. 6A). Our results
also showed that after 5 h of AGE-BSA treatment, the level of nuclear
NF-κBp50 was enhanced (Fig. 6A). These observations were further
veriﬁed by NF-κBp50 speciﬁc ELISA and the results are shown in
Fig. 6D. The co-relation of NF-κB activation and the expression of2 in human chondrocytes. (A) Human OA chondrocytes were treatedwith AGE-BSA for the
eciﬁc siRNA transfection and gene expression of GRP78 and COX-2 in AGE-BSA-stimulated
X-2 in AGE-BSA-stimulated OA chondrocytes. (D) eIF2α-phosphorylation inhibitor 2AP and
h and stimulatedwith AGE-BSA for 24 h. (E) 2AP and protein expression of eIF2α, GRP78
lated with AGE-BSA for 24 h. See Fig. 1 for details. Western immunoblots are from single
n with 95% CI results of three independent experiments, each of which run in triplicate ex-
s chondrocytes transfectedwith control siRNA; **pb0.05 versus chondrocytes treatedwith
Fig. 5. AGE-BSA-induced activation of p38-MAPKs is essential for COX-2 induction during ER stress in human chondrocytes. (A) Human OA chondrocytes were treated with
AGE-BSA for the times indicated and the activation of MAPKs was determined by Immunoblot analysis. GRP78 and COX-2 were indicators for ER stress. (B) Effect of speciﬁc inhib-
itors for MAPKs on the gene expression of GRP78 and COX-2 in AGE-BSA-stimulated OA chondrocytes. (C) Effect of speciﬁc inhibitors for MAPKs on the protein expression of GRP78
and COX-2, and production of PGE2 in AGE-BSA-stimulated OA chondrocytes. OA chondrocytes were pretreated with inhibitors of p38 (SB202190), JNK (SP600125) and ERK
(PD98059) for 1 h and then stimulated with AGE-BSA for 24 h. The concentration of SB202190, SP600125 and PD98059 used in these studies was 100 μM, 10 μM and 50 μM, re-
spectively. Western immunoblots are from single chondrocytes sample, but are representative of ﬁve chondrocytes samples. Bars show the mean with 95% CI results of ﬁve inde-
pendent assays, each of which run in triplicate experiments. *pb0.001 versus chondrocytes treated with AGE-BSA alone; #pb0.0001 versus untreated chondrocytes; $p>0.05
versus chondrocytes treated with AGE-BSA alone.
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pharmacological agent, Bay 11‐7082, a known inhibitor of NF-κB
(IKKα/β). Treatment of primary human OA chondrocytes with Bay
11‐7082, signiﬁcantly blocked the AGE-BSA-induced gene/protein ex-
pression of GRP78 or COX-2 (pb0.05) in human OA chondrocytes
(Fig. 6B and C).
Phosphorylation of the α subunit of eIF2α is required for the activa-
tion of NF-κB in response to ER stress [21]; therefore we examined
whether inhibition of eIF2α-activation by 2-AP treatment or eIF2α-
siRNA knockdown affects the activation of NF-κB subunits p50 or p65
in AGE-BSA-stimulated human OA chondrocytes. Treatment of human
OA chondrocytes with 2-AP or knockdown of eIF2α expression using
speciﬁc siRNAs signiﬁcantly inhibited the activation andDNAbinding ac-
tivity of NF-κBp65 (pb0.05) (Fig. 6E and F) and also inhibited the trans-
location of nuclear NF-κBp50 (data not shown). Similarly, treatment
with p38-MAPK inhibitor SB202190 caused a signiﬁcant decrease in
the DNA binding activity of NF-κBp65 (Fig. 6F) in AGE-BSA stimulated
OA chondrocytes (pb0.05). In contrast, treatment with JNK inhibitor
SP600125 or ERK inhibitor PD98059 had no signiﬁcant effect on
AGE-BSA induced activation of NF-κBp65 (Fig. 6F, p>0.05). Together
these results indicate that activation of NF-κB is dependent on the activa-
tion of p38-MAPK and eIF2α during ER stress in AGE-BSA-stimulated
human OA chondrocytes.
3.7. eIF2α is required to activate the stress-activated p38-MAPK in OA
chondrocytes
Transfection with eIF2α-speciﬁc siRNA (30 nM) signiﬁcantly
inhibited the AGE-BSA-induced phosphorylation of p38-MAPK in OA
chondrocytes (Fig. 6G), indicating that activation eIF2α is upstream
of p38-MAPK and is required for its activation during ER stress in
AGE-BSA-stimulated OA chondrocytes.4. Discussion
This report shows AGEs induce ER stress in human chondrocytes, a
ﬁnding in agreement with previous reports showing that AGEs medi-
ated ER stress in other cell types [36,37]. Iwawaki et al. [38] used a
transgenic mouse model to monitor ER stress in vivo, and demon-
strated that ER stress occurred in a variety of organs such as liver,
spleen, brain, and kidney. However, little is known about the role of
ER stress in cartilage but ER stress likely plays an important role in
cartilage biology as the expression of GRP78 and Bag-1, ER stress
marker proteins, were found to be upregulated several folds in
human as well as in mouse model of arthritis [4,5,39,40]. In addition,
recent reports suggest that multiple outcomes exist following induc-
tion of ER stress in chondrocytes [2,17,40,41]. Despite these advances,
additional studies are needed to fully understand the action of various
inducers of ER stress on chondrocytes and the consequences of ER
stress.
Accumulation of AGEs in articular cartilage has been proposed as a
mechanism for the age-related development of OA [8–10]. The
age-related accumulation of AGEs results in crosslinking of cartilage
matrix components and suggests a putative molecular mechanism
for the development of OA [9]. Therefore, the levels of AGEs might
predict susceptibility for developing OA. In contrast, it is recently
reported that In end stage osteoarthritis, cartilage tissue pentosidine
levels are inversely related to parameters of cartilage damage [42].
This is likely due to the ongoing (ineffective) increased turnover of
cartilage matrix protein even in end stage disease. Moreover, eleva-
tion of cartilage AGEs does not accelerate initiation of canine experi-
mental OA upon mild surgical damage [43]. These data further
support the diminished cartilage turnover in OA, but only a tendency
towards enhanced cartilage damage in AGEs accumulated articular
cartilage. However, in OA chondrocytes, elevated levels of AGEs may
Fig. 6. AGE-BSA-induced activation of NF-κB ismediated through eIF2α or p38-MAPK in human chondrocytes during ER stress. (A) OA chondrocytes were incubatedwith AGE-BSA for the
time indicated and NF-κB subunits were analyzed by Immunoblotting. PARP-1 and Paxillin were used as internal markers for nuclear and cytoplasmic proteins. (B–C) NF-κB inhibitor (BAY
11‐7082) inhibited theAGE-BSA-inducedGRP78 andCOX-2. Chondrocyteswere pretreatedwith Bay 11‐7082 (10 μM) for 1 h and then stimulatedwith AGE-BSA for 24 h. (D)Activation of
NF-κBp50 was further veriﬁed by NF-κBp50 speciﬁc ELISA using nuclear extracts at indicated time intervals. (E) eIF2α-knockdown and NF-κBp65 activation in AGE-BSA-stimulated OA
chondrocytes. eIF2α-knockdown chondrocytes were incubated with AGE-BSA for 45 minutes, and activated NF-κBp65 was determined by ELISA. (F) p38-MAPK and eIF2α inhibitors
inhibited the AGE-BSA-induced activation of NF-κBp65 in chondrocytes. Chondrocytes were pretreated with SB202190, SP600125 and PD98059, 2AP for 1 h and then stimulated with
AGE-BSA for 45 minutes and activated NF-κBp65 was determined ELISA. TNF-α treated HeLa cell extract and Bay 11-7082/AGE-BSA treated chondrocytes extract were used as positive
controls. (G) AGE-BSA-induced phosphorylation of p38-MAPKwas inhibited by eIF2α-knockdown. eIF2α-knockdown chondrocyteswere incubatedwith AGE-BSA for 45 minutes. Immu-
noblots are from single chondrocytes sample, but are representative of ﬁve chondrocytes samples. Bars show themeanwith 95% CI results of ﬁve independent assays, each ofwhich run in
triplicate experiments. *pb0.0001 versus chondrocytes treatedwith AGE-BSA alone; #pb0.0001 versus untreated chondrocytes; ##pb0.001 versus chondrocytes transfected with control
siRNA alone; $pb0.05 versus chondrocytes treated with AGE-BSA+control siRNA; **p>0.05 versus chondrocytes treated with AGE-BSA alone.
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for AGEs) [10,12–14,26]. The activation of RAGE stimulates critical sig-
naling pathways linked to the activation and expression of various in-
ﬂammatory genes [12–14,26]. Studies have shown that abnormally
high levels of COX-2-PGE2 are present in the synovial ﬂuid, synovium
and cartilage tissues of arthritic patients [24,25]. In this study, using pri-
mary human OA chondrocytes, we have demonstrated that in-vitro gen-
erated AGE-BSA activates a RAGE-mediated signaling cascade that
results in the induction of ER stress which leads to increased expression
of COX-2 and PGE2 production. We used AGE-BSA as a model for AGEs,
which is basically a complex that includes N3-carboxymethyllysine
(CML), pentosidine, and other AGEs, produced by reacting BSA with
glycoaldehyde under sterile conditions, followed by extensive dialysis
as previously described [31]. Several lines of evidence support the no-
tion of an interaction of AGE-BSA with RAGE. Knockdown of RAGE by
siRNAs signiﬁcantly inhibited the AGE-BSA‐induced GRP78 and COX-2expression (pb0.05), conﬁrming that AGE-BSA-induced ER stress relat-
ed stimulation of COX-2 expression requires signaling through RAGE. ER
stress and its associated affects on COX-2 expression arewell established
in other cell types [15]. Tunicamycin is a well known ER stress inducer
drug [15,17]. Studies have shown that tunicamycin in various cell
types enhanced COX-2 expression [15,26]. In addition, similar stimula-
tion of COX-2 expression was observed by another ER stress
inducer brefeldin A [15]. These studies clearly indicate that COX-2 is a
part of ER stress. Furthermore, ER stress induced by expression of hepa-
titis B virus surface protein also stimulates the expression of COX-2
in-vitro [15,22] and in-vivo [26]. These studies further support that
COX-2 is a part of ER stress. In the present study, we have established
a relation between ER stress and COX-2 in human chondrocytes for
the ﬁrst time. Treatment of human chondrocytes with tunicamycin, sig-
niﬁcantly increased the expression of COX-2. This again indicating that
COX-2 is a part of ER stress.
Fig. 7. Signaling of endoplasmic stress to COX-2 in AGEs stimulated human chondrocytes. AGEs through RAGE activates eIF2α which relays ER stress signals to the nuclear tran-
scription factor NF-κB via activation of p38-MARK. Different NF-κB complexes were demonstrated by NF-κBp50, NF-κBp65, Rel B and by the proteasomal degradation of IκBα. In-
termediates indicated in blue were not demonstrated in this report. Abbreviations: ER stress: endoplasmic reticulum stress; AGEs: advanced glycation end products; RAGE; receptor
for AGEs; eIF2-α: eukaryotic initiation factor α-2; p38-MAPK: p38-mitogen activated protein kinase; NF-κB; nuclear factor-Κb; COX-2: cyclooxygenase-2.
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ing the eIF2α, MAPK and NF-κB [2,15–17]. These pathways may
cross-talk with each other or converge on common downstream effec-
tors [15,16]. Here we demonstrated that AGE-BSA-induced expression
of COX-2 and PGE2 production required the phosphorylation of eIF2α
during ER stress in human OA chondrocytes. These are novel ﬁndings
and have not been reported previously. In addition, we also demonstrat-
ed that treatment of OA chondrocytes with SB202190 (p38 inhibitor)
signiﬁcantly down regulated the AGE-BSA-stimulated GRP78 and
COX-2 expression and PGE2 production. Whereas, PD98059 (ERK inhib-
itor) or SP600125 (JNK inhibitor) had no effect on AGE-BSA-induced
GRP78 and COX-2 expressions and PGE2 production. But this is in con-
trast to the previous study that showed all MAPK inhibitors (SB202190,
SP600125, PD98059) inhibited AGE-BSA induction of COX-2 expression
and PGE2 production in human OA chondrocytes [26]. Although we
could not ﬁnd how much inhibitors concentrations authors were used
in this study [26], but we cannot rule out of SP600126 or PD98059 in
AGE-BSA stimulated expression of COX-2 and PGE2 production. But our
ﬁndings in the present study demonstrate that AGE-BSA-stimulated ex-
pression of COX-2 and PGE2 productionwasmediated via p38-MAPK ac-
tivation in OA chondrocytes during ER stress.
NF-κB is a transcription factor that participates in immunity and
inﬂammation [44]. NF-κB proteins include p65 (Rel A), Rel B, c-Rel,
p50/p105 and p52/p100, which normally bind to IκB in the cytoplasm
usually in three different complexes [18,44]. It is well documented
that NF-κB is involved in AGE-mediated effects of RAGE signaling
[10,12–14,26] and during ER stress the expression of COX-2 is depen-
dent on the activation of NF-κB [15]. In order to gain further insight
into the mechanism, AGE-BSA induced IκBα degradation and nucleartranslocation of NF-κB p65, p50 and Rel B have been studies in this re-
port (Fig. 6 and 7). Direct effect of NF-κB on COX-2 expression during
ER stress was investigated using the NF-κB (IKKα/β) inhibitor Bay 11‐
7082. Treatment of OA chondrocytes with Bay 11‐7082, signiﬁcantly
blocked the AGE-BSA-induced gene/protein expression of GRP78 or
COX-2 (pb0.05) which showed that AGE-BSA-induced ER stress stim-
ulate the expression of COX-2 via activation of NF-κB.
It has been reported that phosphorylation of eIF2α is required for the
activation of NF-κB in response to ER stress [21]; thereforewe examined
whether inhibition of eIF2α-activation affects the activation of NF-κB in
AGE-BSA-stimulated OA chondrocytes. Treatment of OA chondrocytes
with 2-aminopurine (2AP, an eIF2α inhibitor) or eIF2α-knockdown by
siRNAs signiﬁcantly inhibited the activation and DNA binding activity
of NF-κB (pb0.05) in AGE-BSA-stimulated OA chondrocytes. On the
other hand, treatment with p38-MAPK inhibitor caused signiﬁcant de-
crease in the DNA binding activity of NF-κB in AGE-BSA stimulated OA
chondrocytes (pb0.05). In contrast, treatment with either JNK inhibitor
or ERK inhibitor had no signiﬁcant effect on AGE-BSA induced activation
of NF-κB. These data indicate that activation of p38-MAPK appears to be
essential for the activation of NF-κB in AGE-BSA-stimulated OA
chondrocytes. We also investigated, whether eIF2α is required for the
AGE-BSA-induced activation of p38-MAPK during ER stress. eIF2α
knockdown by eIF2α-speciﬁc siRNAs inhibited the AGE-BSA-induced
phosphorylation of p38-MAPK in OA chondrocytes, indicating that
eIF2α is required for the ER stress-mediated activation of p38-MAPK
in OA chondrocytes. All together these results suggest that activation
of NF-κB is dependent on the phosphorylation of eIF2α and activation
of p38-MAPK during ER stress in AGE-BSA-stimulated human
chondrocytes (data summarized in Fig. 7). In short, our novel data
2188 Z. Rasheed, T.M. Haqqi / Biochimica et Biophysica Acta 1823 (2012) 2179–2189strongly suggest that AGE-BSA-induced ER stress stimulates COX-2 ex-
pression and PGE2 production via activation of eIF2α, p38-MAPK, and
NF-κB pathways in human chondrocytes.
5. Conclusions
This study demonstrates that AGEs stimulate ER stress via RAGE in
human chondrocytes. Activation of RAGE by AGEs induce ER stress
and trigger a cascade of signaling events, which includes phosphory-
lation of eIF2α and p38-MAP kinase which in turn activates NF-κB
and increases the COX-2 expression and PGE2 production. Taken to-
gether, our data suggest that the stress induced by AGEs in the endo-
plasmic reticulum activates multiple signaling pathways that may
play an important role in the degeneration of cartilage in OA. Addi-
tional work is needed to further deﬁne the role of AGEs induced ER
stress in cartilage matrix turnover and to determine if RAGE
mediated-ER stress inhibition could reduce the progression of carti-
lage damage in arthritis.
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